Press release - 01/04/2022 FDA approval for targeted radioligand therapy for treatment of metastatic prostate cancer On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approval-targeted-radioligand-therapy-treatment-metastatic-prostate-cancer
Press release - 30/03/2022 CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-gsk-start-clinical-development-second-generation-covid-19-vaccine-candidate-cv2cov
Press release - 29/03/2022 Biocopy presents "ValidaTe" – A novel ultra-fast screening technology ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months. The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage. New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immune-oncology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/biocopy-presents-validate-novel-ultra-fast-screening-technology
Press release - 21/03/2022 BMBF funds Heidelberg Junior Research Group for 3D Bioprinting Project Junior Professor Dr Daniela Duarte Campos has been awarded a substantial grant from the Federal Ministry of Education and Research (BMBF). She and her junior research group are investigating bioprinting for tissue and organ engineering at the Center for Molecular Biology of Heidelberg University and at the “3D Matter Made to Order” Cluster of Excellence, a collaboration between Ruperto Carola and Karlsruhe Institute of Technology (KIT).https://www.gesundheitsindustrie-bw.de/en/article/press-release/bmbf-funds-heidelberg-junior-research-group-3d-bioprinting-project
Press release - 18/03/2022 Lung Tissue from the Lab Laboratory studies of lung tissue usually require the removal of large amounts of human or animal tissue. Now scientists from the University of Freiburg’s Faculty of Medicine have succeeded in collaboration with American researchers in generating tiny quantities of lung tissue, so-called organoids, from just a few body cells in the lab.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lung-tissue-lab
SolidCAR-T project - 15/03/2022 Modular ‘mini-factories’ for decentralised production of CAR T cells Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.https://www.gesundheitsindustrie-bw.de/en/article/news/modular-mini-factories-decentralised-production-car-t-cells
Press release - 14/03/2022 Do gut bacteria influence treatment success of CAR-T cell therapies? Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
Press release - 10/03/2022 Innovation Day Upper Rhine provides cross-border knowledge transfer Inspiration, innovation, networking are the name of the game on April 12, 2022, when the trinational event “Innovation Day Upper Rhine” (IDUR) takes place at the Palais Universitaire on the University of Strasbourg campus. Twelve universities in the Upper Rhine region, including the University of Freiburg and 100 partner companies of the EU funded project “Knowledge Transfer Upper Rhine” (KTUR), invite to a day of exchange and meeting.https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovation-day-upper-rhine-provides-cross-border-knowledge-transfer
Press release - 03/03/2022 Identifying Alzheimer's risks – as early as 17 years before diagnosis In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?https://www.gesundheitsindustrie-bw.de/en/article/press-release/identifying-alzheimers-risks-early-17-years-diagnosis
Elastin as artificial muscle material - 02/03/2022 Artificial muscle from proteins for diverse future applications As far as diversity and complexity are concerned, proteins are nature's smallest marvels. Biotechnologists have already used natural proteins as a basis for the development, bespoke design and production of artificial systems. This is what the livMatS cluster of excellence at the University of Freiburg has been doing. Researchers in the cluster have successfully produced an artificial muscle from elastin that functions autonomously.https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-muscle-proteins-diverse-future-applications
Press release - 02/03/2022 HPV vaccination: Numerous studies provide impressive proof of effectiveness against cervical cancer More and more data from various European countries prove: Vaccination against human papillomavirus not only prevents precancerous lesions, but also reliably protects against cervical cancer. On the occasion of the International HPV Awareness Day on March 4, Nobel laureate Harald zur Hausen hopes that many more parents will recognize this unique opportunity to protect their children from preventable cancers by vaccinating against HPV.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hpv-vaccination-numerous-studies-provide-impressive-proof-effectiveness-against-cervical-cancer
Press release - 01/03/2022 CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer® The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-gruendet-tochtergesellschaft-zur-weiterentwicklung-des-rna-printer
Press release - 22/02/2022 Better understanding communication between neurons in the brain In the field of optogenetics, scientists investigate the activity of neurons in the brain using light. A team led by Prof. Dr. Ilka Diester and Dr. David Eriksson from the Optophysiology Laboratory at the University of Freiburg has developed a new method to simultaneously conduct laminar recordings, multifiber stimulations, 3D optogenetic stimulation, connectivity inference, and behavioral quantification on brains.https://www.gesundheitsindustrie-bw.de/en/article/press-release/better-understanding-communication-between-neurons-brain
Macrophages interacting with cytomegaloviruses - 22/02/2022 Cytomegaloviruses subvert macrophage identity Cytomegaloviruses are basically harmless. However, if they occur along with other pathogens, they can trigger serious diseases. They can manipulate our immune system and encourage resident defence cells to migrate. Researchers at the Centre for Chronic Immunodeficiency (CCI) at the Freiburg University Medical Centre have discovered which mechanisms underlie the behavioural changes in macrophages that make it easier for other pathogens to attack.https://www.gesundheitsindustrie-bw.de/en/article/news/cytomegaloviruses-subvert-macrophage-identity
Press release - 10/02/2022 CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-participant-phase-1-study-multivalent-influenza-vaccine-candidate-based-second-generation-mrna-backbone-deve
Press release - 08/02/2022 New European Research Council grant for Max Plack Researcher The European Research Council is funding a large-scale proof-of-concept study on a new genome sequencing method called “Haplotagging”. Haplotagging is a new method for sequencing our genome with superior quality and faster speed, developed by group leader Frank Chan and his team at the Friedrich Miescher Laboratory at the Max Planck Campus, Tübingen, Germany.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-european-research-council-grant-max-plack-researcher
Press release - 03/02/2022 The 5G-OR Project is a Winner of the joint Franco-German Program for the Development of innovative Applications for 5G private Networks 5G-OR is one of the 4 winning projects jointly selected by the Federal Ministry of Economics and Climate Action in Germany and the Ministry of Economy, Finance and Relaunch in France for the call “Technical developments and application ecosystems for 5G private networks”. The joint Franco-German 5G-OR project takes up the challenge in the healthcare domain.https://www.gesundheitsindustrie-bw.de/en/article/press-release/5g-or-project-winner-joint-franco-german-program-development-innovative-applications-5g-private-networks
Biosensor for whole blood and exhaled breath analysis - 02/02/2022 Antibiotic detection from whole blood or exhaled breath possible Incorrectly dosed antibiotics are not only dangerous for patients, but also often the cause of resistant strains of bacteria. Researchers at the University of Freiburg have developed a biosensor to determine the effective amount and thus enable personalised therapy. The biosensor works by rapidly determining small amounts of the substances directly from whole blood or exhaled breath.https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotic-detection-whole-blood-or-exhaled-breath-possible
Press release - 31/01/2022 Cancer research learns from space travel Researchers use epigenetic factors to investigate the role of stress in the development of tumor diseases. Experts believe that stress plays a major role in the development of tumors. One occupational group, for example, that experiences extreme stress over a short period of time is astronauts.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-research-learns-space-travel
Press release - 28/01/2022 New insights into predicting the efficacy of active ingredients in drug development Drugs consist of molecules developed in the drug laboratory that bind to their target, usually a protein, and thus exert their effect. The actual duration of binding of a drug molecule to its target protein varies depending on the drug. The lifetime of the drug-target complex can play a critical role in the efficacy of a drug, as a long residence time at the target can be crucial for the drug's action in some cases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-insights-predicting-efficacy-active-ingredients-drug-development
Funding Venture Center of Excellence Funding programme, Funded by: EIT Health e.V. und European Investment Fund (EIF), sb_search.searchresult.label.programSubmissionDate: 31/12/2024 https://www.gesundheitsindustrie-bw.de/en/database/funding/venture-center-excellence
Funding Venture Center of Excellence Funding programme, Funded by: EIT Health e.V. und European Investment Fund (EIF), sb_search.searchresult.label.programSubmissionDate: 31/12/2024 https://www.gesundheitsindustrie-bw.de/en/database/funding/venture-center-excellence
Press release - 28/01/2022 Artificial Muscles Made of Proteins Dr. Stefan Schiller and Dr. Matthias Huber from the University of Freiburg’s livMatS Cluster of Excellence have succeeded in developing a muscle solely on the basis of natural proteins. The autonomous contractions of the material, which the researchers presented in the journal Advanced Intelligent Systems, can be controlled with the help of pH and temperature changes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/artificial-muscles-made-proteins
Viral zoonoses - 24/01/2022 Development of inhibitors that help stop viral zoonoses Emerging viral infections such as COVID-19 or Zika disease pose an increasing threat to humans. At the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University, Prof. Dr. Christian Klein's research group is developing inhibitors against already known viruses in the hope that these can also be used against new virus variants.https://www.gesundheitsindustrie-bw.de/en/article/news/development-inhibitors-help-stop-viral-zoonoses
microRNA as a prognostic biomarker - 13/01/2022 Heart attack diagnosis: fast and unambiguous thanks to artificial intelligence People that arrive in emergency rooms with chest pain require swift action in order to rule out a heart attack or to initiate vital life-saving therapy. However, despite many advances, current tests are not yet optimal: they either take hours or produce false-positive results. Researchers at Heidelberg University Hospital are now using AI in an approach that takes microRNAs from a blood sample to specifically diagnose ‘acute coronary syndrome’.https://www.gesundheitsindustrie-bw.de/en/article/news/heart-attack-diagnosis-fast-and-unambiguous-thanks-artificial-intelligence